In March 2016, participant recruitment for a Phase II study (NCT01951495) in relapsing/recurring MM patients employing AKT inhibitor GSK2141795 and MET blocker trametinib was suspended without explanation. The gene discussed is AKT1; the disease is Miyoshi myopathy.